



FOR IMMEDIATE RELEASE

Obtained Renewal of Imported Drug License for Ferplex[®] Iron Proteinsuccinylate Oral Solution in China

(Hong Kong, 14 January 2010) – Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221; Website: www.leespharm.com) ("Leespharm") announced today that the Group has successfully obtained the renewal of Imported Drug License ("IDL") for marketing of Ferplex[®] (Iron Proteinsuccinylate Oral Solution), in the People's Republic of China.

Leepharm has partnered with Italfarmaco S.p.A., an Italian pharmaceutical company, to market Ferplex[®] exclusively in China since the fourth quarter of 2007. Ferplex[®], a patented formulation indicated for iron deficiency anaemia, is prescribed across a wide range of patient groups for all ages. With its superior tolerability profile of minimum gastrointestinal side effects, Ferplex[®] is especially suitable for pregnant and lactating women as well as infants and children.

"We're extremely pleased with the successful renewal of IDL for Ferplex[®]. This achievement will enable us to continue our aggressive expansion of the market in China. Since we relaunched the product in late 2007, we have been able to grow the product significantly, recording a 210% increase in 2009 over 2008," stated Dr. Benjamin Li, the Chief Executive Officer of the Group. "We are looking forward to having significant contribution from this product to the Group's growth in the near future!"

About Iron Deficiency Anemia

In the iron deficiency anemia a failure of the medullar function of hemoglobin synthesis exists for iron lack. Iron deficiency is a previous step, in which a decrease of the systemic deposits of iron exists. The metabolism of the iron is complex, with intervention of multiple factors. Infants and children are at particular risk of iron deficiency due to high demands for iron during a period of rapid growth and because their diet is often low in available iron. The treatment should be etiologic whenever it is possible; the oral supplementation constitutes a fundamental pillar, to which one adds a nutritional appropriate contribution.

About ITALFARMACO

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas. The Group is particularly active in the

field of research, mainly oriented towards the cardiovascular area and disease associated with alterations of the immunological system. For more information about Italfarmaco and the company's product pipeline, please visit at : www.italfarmaco.it

About LEESPHARM

Lee's Pharmaceutical Holdings Limited, a specialty biopharmaceutical company operating in China for over 14 years, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002. It is a fully integrated biopharmaceutical company with a solid infrastructure in both drug and clinical development. In addition, it carries out regulatory matters as well as manufacturing, sales and marketing activities throughout China. Lee's currently markets six products in China, and focuses its development efforts on various clinical areas, including cardiovascular and infectious diseases, dermatology, oncology, gynecology and others with more than 15 products currently at different development stages. This is the result of both internal R&D activities as well as from their recent acquisition of licensing and distribution rights from various US, Japan and European partners.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com